Glaukos Corporation (GKOS) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Glaukos Corporation (GKOS) right now is iDose TR ramp: The iDose TR sustained-release glaucoma implant is the single biggest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma franchise up roughly 58% year over year. Revenue (TTM) is ~$470M. If that keeps playing out, the setup is favourable; the risk to it is glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. No one can predict where GKOS trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Glaukos Corporation (GKOS) higher?
1. iDose TR ramp
The iDose TR sustained-release glaucoma implant is the single biggest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma franchise up roughly 58% year over year. Its adoption reflects a shift toward procedural, drug-eluting glaucoma care rather than daily eye drops. Continued reimbursement clarity and a growing base of peer-reviewed clinical evidence support the ramp.
2. Corneal health and Epioxa
The corneal-health segment (Photrexa and the newer Epioxa incision-free cross-linking therapy for keratoconus) is a second growth engine. A CMS permanent J-code for Epioxa helps de-risk near-term reimbursement and access as the launch scales. This diversifies Glaukos beyond glaucoma devices into rare corneal disease.
3. International expansion
International glaucoma procedures are growing, aided by the European commercial launch of iStent Infinite following EU MDR certification. Overseas markets broaden the addressable base beyond the US. This gives Glaukos additional runway even as domestic MIGS competition intensifies.
4. Path toward profitability
Rapid top-line growth combined with a debt-free balance sheet and roughly $280 million in cash gives Glaukos room to invest through its launches. Gross profit rose about 42% in Q1 2026, tracking sales. The open question is how quickly operating leverage turns the current net losses into sustained profit.
What could weigh on GKOS?
Glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Reimbursement complexity is a recurring watchpoint, including Medicaid Drug Rebate Program impacts that have muted Photrexa and general pricing pressure in glaucoma devices. Competition is intense from Alcon, Sight Sciences, AbbVie, Johnson & Johnson, and others across MIGS and glaucoma drug delivery, and a competitor supply recovery or new launch could erode share. The legacy iStent business has shown flattish trends outside iDose, and international markets face new competitive product trialing. Heavy spending relative to current earnings means execution and continued access to capital both matter.
Where GKOS trades today
A forecast starts from where the stock actually is. These are GKOS's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for GKOS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a GKOS forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the GKOS guide and whether GKOS is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the GKOS outlook
The bottom line: what is driving Glaukos Corporation (GKOS) is iDose TR ramp, with revenue (ttm) at ~$470M. If that keeps playing out the setup is favourable; the risk is glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. No one can predict the price, so treat any GKOS forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around GKOS with Walnut
Use Glaukos Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Glaukos Corporation (GKOS)?
+
No one can reliably predict where GKOS will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Glaukos Corporation higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive GKOS higher?
+
The main growth drivers are iDose TR ramp; Corneal health and Epioxa; International expansion. Whether they play out is the real question, not a guaranteed path.
What are the risks to GKOS?
+
Glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Reimbursement complexity is a recurring watchpoint, including Medicaid Drug Rebate Program impacts that have muted Photrexa and general pricing pressure in glaucoma devices. Competition is intense from Alcon, Sight Sciences, AbbVie, Johnson & Johnson, and others across MIGS and glaucoma drug delivery, and a competitor supply recovery or new launch could erode share. The legacy iStent business has shown flattish trends outside iDose, and international markets face new competitive product trialing. Heavy spending relative to current earnings means execution and continued access to capital both matter.
Will GKOS stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Glaukos Corporation's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is GKOS a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the GKOS "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is Glaukos growing?
+
Very fast for a medtech company. Q1 2026 net sales rose about 41% year over year to roughly $150.6 million, and management raised full-year 2026 guidance to about $620 million to $635 million. The US glaucoma franchise grew roughly 58% year over year (as of May 2026).
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.